In the 24-week results of its phase 2b trial in MASH, the inflammatory form of the disease, MASH resolved in 58% on 1.2 mg and 52% on 1.8 mg, against 20% on placebo. We found no label for it on DailyMed on November 20, 2026.1,2
What it is
A 2025 trial report in the Journal of Hepatology describes pemvidutide as a GLP-1 and glucagon dual receptor agonist.3 Pairing GLP-1 with glucagon, whose main target is the liver, makes liver fat and liver inflammation natural places to test it. In the trials described here it was injected under the skin once a week, and in IMPACT it was given without a dose climb, starting at the full dose.1
The liver fat trial
The earlier trial enrolled 94 adults with a body mass index of 28 or more and liver fat of at least 10% on MRI, 29% of whom had type 2 diabetes. They took pemvidutide 1.2, 1.8 or 2.4 mg, or placebo, for 12 weeks.3
- Liver fat fell by 46.6%, 68.5% and 57.1% on the three doses, against 4.4% on placebo.
- On 1.8 mg, 94.4% reduced liver fat by at least 30%, and 55.6% brought it down to 5% or less, the normal range.
- Weight fell by up to 4.3% over the 12 weeks, and the liver enzyme ALT, a blood marker of liver cell injury, fell as well.
J Hepatol 2025.3
IMPACT, the MASH trial
IMPACT is a 48-week phase 2b trial in people with biopsy-confirmed MASH and moderate to advanced scarring, stage F2 or F3, at 83 sites in the United States and Australia. Of 1,557 people screened, 212 were assigned in a 1:2:2 ratio to placebo, 1.2 mg or 1.8 mg. The published results cover week 24.1
- MASH resolved without worse scarring in 20% on placebo, 58% on 1.2 mg and 52% on 1.8 mg.
- Scarring improved by at least one stage without worse MASH in 28%, 33% and 36%; neither difference from placebo was statistically clear.
- Adverse events were reported by 67% on placebo, 78% on 1.2 mg and 81% on 1.8 mg, most mild or moderate.
Noureddin et al., 2025.1
Starting at the full dose
IMPACT gave pemvidutide at its full dose from the first injection, without the step-by-step climb that the approved GLP-1 medicines use to soften stomach side effects. Adverse events were more common on the drug, at 78% and 81% against 67% on placebo, though most were mild or moderate.1 Whether a climb would be needed in wider use is one of the questions later trials will answer.
How to read the results
Like other drugs of this kind, pemvidutide cleared liver inflammation faster than it reversed scarring, at least by week 24. The same pattern appeared in the tirzepatide trial SYNERGY-NASH, where the effect on MASH resolution was large and the effect on scarring smaller.4 Wegovy, which has a label for this condition, improved both in its 72-week trial: MASH resolved in 63% against 34%, and scarring improved in 37% against 22%.5 IMPACT's full 48-week results will show whether scarring catches up.
Limits
IMPACT was funded by Altimmune, the developer, and several authors of the earlier trial work for the company. Both trials are short: 12 weeks for liver fat and 24 weeks for the published IMPACT results. Pemvidutide is a trial medicine without a U.S. label.1,2 Our page on nausea on a GLP-1 covers the most common side effect of the class.
Sources
- Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025;406:2644-2655. Funded by Altimmune; NCT05989711. doi:10.1016/S0140-6736(25)02114-2
- DailyMed, U.S. National Library of Medicine. Search for "pemvidutide", no results; read November 20, 2026. dailymed.nlm.nih.gov
- Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol 2025;82:7-17. Several authors are affiliated with Altimmune. doi:10.1016/j.jhep.2024.07.006
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. doi:10.1056/NEJMoa2401943
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1 and 14. accessdata.fda.gov
Related analyses
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
Log any GLP-1 medicine you take with your liver test results over time.
Open Dose Insider